Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Acrivon Therapeutics, Inc. (ACRV)
Jefferies Upgrades Vistagen Therapeutics to Buy, Raises Price Target to $15
Vistagen Therapeutics Analyst Ratings
Hearing Vistagen Therapeutics Upgraded From A Hold To A Buy At Jefferies; Price Target $15
Vistagen Therapeutics Analyst Ratings
VistaGen Therapeutics' Robust Financial Position and Promising Pipeline Underpin Buy Rating: A Comprehensive Analysis
Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Rhythm Pharmaceuticals (RYTM)
Maxim Cuts Price Target on VistaGen Therapeutics to $12 From $30, Maintains Buy Rating
Maxim Group Reaffirms Their Buy Rating on VistaGen Therapeutics (VTGN)
Analysts Offer Insights on Healthcare Companies: CymaBay Therapeutics (CBAY) and VistaGen Therapeutics (VTGN)
Maxim Group Maintains Buy on Vistagen Therapeutics, Maintains $30 Price Target
Vistagen Therapeutics Analyst Ratings
Maxim Group Remains a Buy on VistaGen Therapeutics (VTGN)
Maxim Group Upgrades Vistagen Therapeutics to Buy, Announces $30 Price Target
Vistagen Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Humacyte (HUMA)
Maxim Group Sticks to Their Hold Rating for VistaGen Therapeutics (VTGN)
Maxim Group Sticks to Its Hold Rating for VistaGen Therapeutics (VTGN)
Robert W. Baird Reaffirms Their Hold Rating on VistaGen Therapeutics (VTGN)